Skip to main content

Table 2 Serum folate levels according to genotype and case–control status

From: Complex interaction between serum folate levels and genetic polymorphisms in folate pathway genes: biomarkers of prostate cancer aggressiveness

 

Cases

adjusted serum folate nmol/L mean ± SDa (median)

P Trend

Controls

adjusted serum folate nmol/L mean ± SDa (median)

P Trend

MTHFR C677T

CC

12.8 ± 0.4 (10.7)

0.155

9.8 ± 0.4 (9.1)

0.091

CT

11.8 ± 0.7 (10.1)

9.2 ± 0.7 (9.1)

TT

7.0 ± 1.7 (6.1)

MTHFR A1298C

AA

12.4 ± 0.4 (12.4)

0.523

9.6 ± 0.4 (8.9)

0.898

AC

13.0 ± 0.7 (13.8)

 

9.5 ± 0.7 (9.8)

CC

12.8 ± 1.4 (11.6)

 

9.6 ± 1.72 (9.0)

MTRR A66G

AA

12.1 ± 0.4 (12.0)

0.511

9.5 ± 0.4 (9.3)

0.944

AG

13.4 ± 0.5 (13.1)

9.5 ± 0.6 (8.6)

GG

12.1 ± 1.1 (12.2)

9.6 ± 1.3 (8.1)

MTR A2756G

AA

12.4 ± 0.5 (11.9)

0.693

9.6 ± 0.5 (8.7)

0.525

AG

13.0 ± 0.5 (13.0)

9.2 ± 0.5 (9.0)

GG

11.8 ± 0.9 (11.3)

10.6 ± 0.9 (10.7)

MTHFR C677T/A1298C

CC + AA

12.8 ± 0.4 (12.7)

0.295

10.0 ± 0.5 (9.0)

0.228

CC + (AC + CC)

12.8 ± 0.6 (12.6)

9.3 ± 0.7 (9.3)

(CT + TT) + AA

11.1 ± 0.8 (10.5)

8.6 ± 0.7 (8.4)

(CT + TT) + (AC + CC)

13.7 ± 1.4 (14.2)

11.0 ± 1.9 (12.4)

  1. aSerum folate means adjusted for vitamin use